Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF) with antiangiogenic properties, has been implicated as an antitumor immune modulator in patients with ovarian cancer, colorectal cancer, and other malignant effusions [71, 72, 73]. This evidence concerns the gene VEGFA and ovarian cancer.